The effect of sodium-glucose cotransporter-2 inhibitors on cardiovascular biomarkers and left ventricular function in patients with type 2 diabetes and concomitant cardiovascular disease
In patients with T2DM and established CVD, SGLT2i therapy was associated with significant improvements in left ventricular function and reductions in HF-related biomarkers, supporting the cardioprotective and nephroprotective effects of this drug class.
Authors
- Anna Maj-Podsiadło (ORCID: https://orcid.org/0000-0002-4790-298X)
- Janusz Gumprecht (ORCID: https://orcid.org/0000-0001-7091-2118)
- Edyta Cichocka (ORCID: https://orcid.org/0000-0002-0125-4323)
Institutions
- Medical University of Silesia (PL)
Publication Details
- Journal
- Endokrynologia Polska
- Published
- 2025-12-03
- DOI
- https://doi.org/10.5603/ep.107260
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00